glucagon has been researched along with orlistat in 6 studies
| Studies (glucagon) | Trials (glucagon) | Recent Studies (post-2010) (glucagon) | Studies (orlistat) | Trials (orlistat) | Recent Studies (post-2010) (orlistat) |
|---|---|---|---|---|---|
| 26,039 | 1,498 | 3,054 | 1,432 | 274 | 539 |
| Protein | Taxonomy | glucagon (IC50) | orlistat (IC50) |
|---|---|---|---|
| Phosphatidylserine lipase ABHD16A | Homo sapiens (human) | 0.1 | |
| Pancreatic triacylglycerol lipase | Sus scrofa (pig) | 0.4214 | |
| Lipoprotein lipase | Homo sapiens (human) | 0.066 | |
| Cytochrome P450 3A4 | Homo sapiens (human) | 0.42 | |
| Hepatic triacylglycerol lipase | Homo sapiens (human) | 0.003 | |
| Pancreatic triacylglycerol lipase | Homo sapiens (human) | 0.3253 | |
| Translocator protein | Rattus norvegicus (Norway rat) | 1 | |
| Cytochrome P450 2C19 | Homo sapiens (human) | 0.42 | |
| Kappa-type opioid receptor | Mus musculus (house mouse) | 0.1903 | |
| Fatty acid synthase | Homo sapiens (human) | 2.99 | |
| Fatty-acid amide hydrolase 1 | Rattus norvegicus (Norway rat) | 0.01 | |
| Platelet-activating factor acetylhydrolase | Homo sapiens (human) | 0.05 | |
| Diacylglycerol lipase-alpha | Mus musculus (house mouse) | 0.02 | |
| Lysophosphatidylserine lipase ABHD12 | Homo sapiens (human) | 0.1682 | |
| Diacylglycerol lipase-beta | Homo sapiens (human) | 0.24 | |
| Monoacylglycerol lipase ABHD6 | Homo sapiens (human) | 0.03 | |
| Acyl-protein thioesterase 2 | Rattus norvegicus (Norway rat) | 0.17 | |
| Diacylglycerol lipase-alpha | Homo sapiens (human) | 0.2677 | |
| Endothelial lipase | Homo sapiens (human) | 0.006 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Boyd, AE; Civelek, VN; Corkey, BE; Deeney, JT; Dillon, JS; Hamilton, JA; Korchak, HM; Richard, AM; Tornheim, K; Yaney, GC | 1 |
| Bryant, L; Feinle, C; Horowitz, M; Jones, KL; Lei, Y; Meyer, JH; O'Donovan, D; Pilichiewicz, A; Wishart, JM | 1 |
| Balci, H; Damci, T; Ilkova, H; Korugan, U; Osar, Z; Ozyazar, M; Yalin, S | 1 |
| Feinle-Bisset, C; Horowitz, M; Jones, K; Nauck, M | 1 |
| Ballaux, D; Mertens, I; Van Gaal, L; Verkade, HJ | 1 |
| Feinle-Bisset, C; Gentilcore, D; Horowitz, M; Jones, KL; Morris, HA; Murolo, N; O'Donovan, D; Russo, A; Wishart, JM | 1 |
1 review(s) available for glucagon and orlistat
| Article | Year |
|---|---|
Modern, new pharmacotherapy for obesity. A gastrointestinal approach.
Topics: Amylases; Androgens; Anti-Obesity Agents; Citrates; Cyclobutanes; Dietary Fats; Fat Substitutes; Fatty Acids; Glucagon; Glucagon-Like Peptide 1; Glucosidases; Human Growth Hormone; Humans; Intestinal Absorption; Lactones; Lipase; Obesity; Orlistat; Peptide Fragments; Protein Precursors; Sucrose | 2004 |
2 trial(s) available for glucagon and orlistat
| Article | Year |
|---|---|
Effect of lipase inhibition on gastric emptying of, and the glycemic and incretin responses to, an oil/aqueous drink in type 2 diabetes mellitus.
Topics: Autonomic Nervous System; Blood Glucose; Diabetes Mellitus, Type 2; Dietary Fats; Enzyme Inhibitors; Female; Gastric Emptying; Gastric Inhibitory Polypeptide; Gastric Mucosa; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptides; Glucose; Hemodynamics; Humans; Insulin; Lactones; Lipase; Male; Middle Aged; Orlistat; Peptide Fragments; Peptides | 2003 |
Orlistat augments postprandial increases in glucagon-like peptide 1 in obese type 2 diabetic patients.
Topics: Adult; Aged; Anti-Obesity Agents; Cross-Over Studies; Diabetes Mellitus; Diabetes Mellitus, Type 2; Female; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Humans; Insulin; Lactones; Male; Middle Aged; Obesity; Orlistat; Peptide Fragments; Protein Precursors; Single-Blind Method; Weight Loss | 2004 |
3 other study(ies) available for glucagon and orlistat
| Article | Year |
|---|---|
Glucagon-like peptide 1 stimulates lipolysis in clonal pancreatic beta-cells (HIT).
Topics: Calcium; Cell Line; Enzyme Inhibitors; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptides; Hydrogen-Ion Concentration; Intracellular Membranes; Islets of Langerhans; Lactones; Lipase; Lipolysis; Orlistat; Peptide Fragments; Protein Precursors; Sterol Esterase | 2001 |
Orlistat augments postprandial increases in glucagon-like peptide-1 in obese type 2 diabetic patients: response to Damci et al.
Topics: Anti-Obesity Agents; Diabetes Mellitus, Type 2; Glucagon; Glucagon-Like Peptide 1; Humans; Lactones; Obesity; Orlistat; Peptide Fragments; Postprandial Period; Protein Precursors | 2004 |
Effects of lipase inhibition on gastric emptying of, and on the glycaemic, insulin and cardiovascular responses to, a high-fat/carbohydrate meal in type 2 diabetes.
Topics: Aged; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Dietary Carbohydrates; Dietary Fats; Enzyme Inhibitors; Female; Gastric Emptying; Glucagon; Glucagon-Like Peptide 1; Heart Rate; Humans; Insulin; Insulin Secretion; Lactones; Lipase; Male; Middle Aged; Orlistat; Peptide Fragments; Protein Precursors | 2004 |